Pharmacy Guild fears heavy discounts threaten industry

The discounting has been sparked by the entry of more than a dozen generic atorvastatins to the market as the patent for Pfizer’s drug Lipitor ended and manufacturers and retailers moved to shore up market share.

Manufacturer Ranbaxy fired the opening salvo late last month, giving selected pharmacies up to $14,500 worth of its generic, Trovas, and offering subsequent discounts of 90% on the government-listed price.

More recently, pharmacy chain Chemist Warehouse triggered a TGA investigation by advertising the availability